PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negativ...

Post time The day before yesterday 07:18

journal：Journal of Clinical Oncology

Authors：Erica L. Mayer; Yue Ren; Nikhil Wagle; Reshma Mahtani; Cynthia Ma; Angela DeMichele; Massimo Cristofanilli; Jane Meisel; Kathy D. Miller; Yara Abdou; Elizabeth C. Riley; Rubina Qamar; Priyanka Sharma; Sonya Reid; Natalie Sinclair; Meredith Faggen; Caroline C. Block; Naomi Ko; Ann H. Partridge; Wendy Y. Chen; Michelle DeMeo; Victoria Attaya; Amanda Okpoebo; Jillian Alberti; Yuan Liu; Eric Gauthier; Harold J. Burstein; Meredith M. Regan; Sara M. Tolaney

Published date：2024-6-10

DOI：10.1200/jco.23.01940

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01940

Article link：http://dx.doi.org/10.1200/jco.23.01940

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time The day before yesterday 07:18

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negativ...

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negativ... Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negativ...